Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTIM-76 in Advanced Solid Tumors
NCT06515613Phase 1Recruiting
- Sponsor
- Context Therapeutics
- Start
- Jul 2024
- Primary completion
- May 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CTIM-76 in ovarian cancer, testicular cancer and endometrial cancer (EC), sponsored by Context Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Overall Response Rate up to 24 months. Started Jul 2024; status: recruiting.
02
Drugs
CTIM-76
03
Conditions
ovarian cancertesticular cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06515613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515613.